Fast Market Research recommends "Hyperparathyroidism - Analysis and Market Forecasts to 2019" from GlobalData, now available
Boston, MA -- (SBWIRE) -- 11/30/2012 -- The global hyperparathyroidism therapeutics market is forecast to grow to reach $2.6 billion by 2019. This moderate growth is primarily attributed to the increase in the hyperparathyroidism patient population and the expected launches of two novel drugs: CTAP101 and KAI-4169 IV. The major barriers for the hyperparathyroidism therapeutics market during forecast period are the introduction of bundled dialysis payment system in the US and the expected patent expirations of all three leading branded drugs in the market: Sensipar/Mimpara, Zemplar and Hectorol. The hyperparathyroidism pipeline is weak, with only seven molecules in various stages of development, including four first-in-class molecules and three me-too products. Amgen and Abbott are the leading companies in the current competitive landscape. Amgen is likely to maintain its position during the forecast period due to its acquisition in July 2012 of KAI Pharmaceuticals and its promising pipeline molecule KAI-4169.
View Full Report Details and Table of Contents
- Overview of hyperparathyroidism, including epidemiology, etiology, symptoms, diagnosis, pathophysiology, management and treatment guidelines.
- Annualized hyperparathyroidism therapeutics market revenue, annual cost of therapy and forecast for eight years to 2019.
- Pipeline analysis: Comprehensive data split across different phases, emerging trends and mechanisms of action under development, including calcium sensing receptor agonist, vitamin D pro-hormone, vitamin D receptor agonist and CYP24 enzyme inhibitor.
- Analysis of the current and future market competition in the global hyperparathyroidism therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the hyperparathyroidism therapeutics market.
Reasons to Get this Report
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global hyperparathyroidism therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hyperparathyroidism therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Companies Mentioned in this Report: Amgen Inc., Abbott Laboratories, Cytochroma Inc., KAI Pharmaceuticals Inc.
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- End-stage Renal Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2019
- Hyperparathyroidism Therapeutics - Pipeline Assessment and Market Forecasts to 2017
- Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar
- Nasopharyngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019
- Syphilis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
- Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
- Hereditary Angioedema Therapeutics - Pipeline Assessment and Market Forecasts to 2019
- Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
- Overactive Bladder (OAB) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
- Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)